Similarly, 3xTg-AD mice treated with CpG ODN exhibited an overall decrease in hippocampal CD206 (marker of M2 state of alternative activation) immunoreactivity at the end of the treatment (two-tailed t test, 7–20 months, *p = 0.04; 11–18 months, *p = 0.013, Figure 12G-L). The gene discussed is MRC1; the disease is Alzheimer disease.